PHOENIX - TelAve -- Since introducing Nanosecond Pulsed Field Ablation (nsPFA™) treatment in 2025, Richard J. Harding, MD, FACS, has continued to expand access to this non‑surgical option for patients with symptomatic benign thyroid nodules. As one of the earliest U.S. physicians to adopt nsPFA™, Dr. Harding is now seeing increased interest from primary care providers, endocrinologists, and ENT specialists seeking alternatives to conventional thyroid surgery.

Pulse Biosciences, the developer of nsPFA™ technology, recognizes Dr. Harding's leadership in bringing this innovative, non‑thermal ablation method to patients in the Phoenix region.

"nsPFA represents a meaningful advancement in thyroid nodule care," said Doug Polzin of Pulse Biosciences. "Traditional thermal ablation methods such as RFA and microwave ablation rely on heat, which can pose risks to surrounding structures. nsPFA uses ultra‑short electrical pulses to precisely target nodule tissue while preserving nearby nerves and critical anatomy. We're excited to see physicians like Dr. Harding bringing this technology to patients who want a safe, effective, non‑surgical option.

More on TelAve News

• Norisia Launches AI Formulated Luxury Multivitamin to Transform Daily Wellness in the UK
• Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
• NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
• When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age
• Half of Finnish Online Gambling Expenditure Now Flows to Offshore Instant Casinos as License Applications Open March 1, 2026

Benign thyroid nodules are common and can cause pressure, discomfort, difficulty swallowing, or cosmetic concerns. Historically, patients seeking relief often faced limited choices: monitoring, medication, or surgery. nsPFA™ offers a new pathway—one that precisely targets nodule tissue while preserving surrounding structures and avoiding the risks associated with heat‑based ablation.

https://youtu.be/1eG6x0W9CW0?si=VROgIiIq4JDzKSns



"In my practice, nsPFA™ has shown excellent outcomes with minimal downtime," said Dr. Harding. "Patients appreciate having a non‑surgical option that preserves thyroid function and allows them to return to normal activities quickly."

About the Thyroid Nodule Treatment Center:
The Thyroid Nodule Treatment Center, specializes in the diagnosis and treatment of thyroid nodules. The mission of the Thyroid Nodule Treatment Center (TNTC) is the preservation of normal thyroid function while treating benign symptomatic thyroid nodules using the most advanced minimally invasive treatments available. Under the expert leadership of Dr. Richard Harding, the center is committed to providing patients with the latest and most effective treatment options in a compassionate and supportive environment.

More on TelAve News

• RTC Communications Completes Next Level Connect Fiber Expansion Bringing Multi-Gig Broadband to West Boggs Community
• EPP Pricing Platform announces leadership transition to support long-term growth and continuity
• Stolen Hearts: Reclaiming Your Child From Parental Alienation (narcissistic abuse)
• Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
• Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount

2320 N. Third Street
Phoenix, AZ 85004
https://thyroidnoduletreatment.center

About Pulse Biosciences, Inc.
Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
3957 Point Eden Way, Hayward, CA 94545
http://www.pulsebiosciences.com